XKRX
000520
Market cap132mUSD
Oct 08, Last price
8,350.00KRW
1D
-2.11%
1Q
32.96%
Jan 2017
126.04%
Name
Samil Pharmaceutical Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Samil Pharmaceutical Co., Ltd. is a South Korean pharmaceutical company founded in 1947 that develops, manufactures, and sells a range of healthcare products. While its portfolio includes various medicines and medical devices, it has a particular specialization in ophthalmology (eye care). The company engages in the development of new drugs and also provides Contract Development and Manufacturing Organisation (CDMO) services.
Key people
President, Director · since 2025
Seung Beom Huh
Chairman of the Board, Chief Executive Officer · since 2025
Bu Hwan Goh
Vice President, Director · since 2011
Jun Beom Huh
Managing Director
Jong Pyo Hong
Assistant Managing Director
Assistant Managing Director
Gi Dong Kim
Internal Auditor
Tae Gyeong Kim
Assistant Managing Director
Gyeong Cheol Oh
Assistant Managing Director
Gi Jeong Lee
Director
Jong Nam Kim
Non-Executive Independent Director · since 2007
Hyeong Wuk Kim
Non-Executive Independent Director
Chang Ho Kim
Non-Executive Independent Director
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||